Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T21:33:48.455Z.
Calculation as of: 2026-10-06T21:33:48.455Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9e5af3e3eb74887b0741ac42ed15d75d820cdffcd327c1f2ecbbd665592eb47e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$349.70M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.88M
EV/FCF Ratio
N/A
TTM Avg
50.02x
3Y Avg
37.43x
5Y Avg
35.40x
Market Cap
$355.36M
EV/FCF Ratio
12.19x
TTM Avg
33.56x
3Y Avg
51.03x
5Y Avg
195.24x
Market Cap
$355.43M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $344.04M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 9.96x | 9.65x | 69.46x | 48.92x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A | 50.02x | 37.43x | 35.40x |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 12.19x | 33.56x | 51.03x | 195.24x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
